Basisstatistiken
| LEI | 2138001XURASAU3MEB68 |
| CIK | 1541157 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Celsus Therapeutics
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 22, 2026 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 22, 2026 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 22, 2026 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 22, 2026 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 22, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 20, 2026, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively |
|
| May 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2026 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi |
|
| May 21, 2026 |
Akari Therapeutics, Plc 401 East Jackson Street, Suite 3300 Tampa, FL 33602 Akari Therapeutics, Plc 401 East Jackson Street, Suite 3300 Tampa, FL 33602 May 20, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Ther |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2026 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio |
|
| May 8, 2026 |
Exhibit 4.11 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC. Warrant No. [●] Issuance Date: [●], 2026 Number of American Depositary Shares: [●] THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, A.G.P./Alliance Global Partners or |
|
| May 8, 2026 |
Exhibit 4.8 SERIES H WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC. Warrant No. [●] Issuance Date: [●], 2026 Number of American Depositary Shares: [●] THIS SERIES H WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon t |
|
| May 8, 2026 |
Exhibit 4.10 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC. Warrant No. [●] Issuance Date: [●], 2026 Number of American Depositary Shares: [●] THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, u |
|
| May 8, 2026 |
As filed with the Securities and Exchange Commission on May 8, 2026. As filed with the Securities and Exchange Commission on May 8, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKARI THERAPEUTICS, PLC (Exact name of registrant as specified in its charter) England and Wales 2834 98-1034922 (State or other jurisdiction of incorporation or organizati |
|
| May 8, 2026 |
Exhibit 4.9 SERIES I WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC. Warrant No. [●] Issuance Date: [●], 2026 Number of American Depositary Shares: [●] THIS SERIES I WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon t |
|
| May 8, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May [●], 2026, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectivel |
|
| May 8, 2026 |
Calculation of Filing Fee Tables S-1 Akari Therapeutics Plc Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Ordinary shares, nominal value $0. |
|
| May 8, 2026 |
[The remainder of this page has been intentionally left blank.] Exhibit 10.2 [●], 2026 Akari Therapeutics, Plc Attn: Abizer Gaslightwala, Chief Executive Officer 401 East Jackson Street, Suite 3300 Tampa, FL 33602 Dear Mr. Gaslightwala: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England |
|
| April 10, 2026 |
As filed with the Securities and Exchange Commission on April 10, 2026 As filed with the Securities and Exchange Commission on April 10, 2026 Registration No. |
|
| April 2, 2026 |
Exhibit 4.8 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC. Warrant No. [●] Issuance Date: [●], 2026 Number of American Depositary Shares: [ ] THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled |
|
| April 2, 2026 |
As confidentially submitted to the Securities and Exchange Commission on April 2, 2026. |
|
| April 2, 2026 |
Exhibit 4.7 SERIES H WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC. Warrant No. [●] Issuance Date: [●], 2026 Number of American Depositary Shares: [●] THIS SERIES H WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, up |
|
| March 30, 2026 |
Exhibit 4.7 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description is a summary of the material terms of Akari Therapeutics, Plc’s (the “Company”) ordinary shares with a par value $0.0001 per share and American Depositary Shares (the “ADSs”), each representing 2,000 ordinary shares. This description also summarizes r |
|
| March 30, 2026 |
Subsidiaries of Akari Therapeutics, Plc Exhibit 21.1 Subsidiaries of Akari Therapeutics, Plc The following table sets forth the name and jurisdiction of incorporation of our subsidiaries: Name of Subsidiary Jurisdiction of Incorporation Celsus Therapeutics Inc. Delaware Morria Biopharma Ltd. Israel Volution Immuno Pharmaceuticals SA Switzerland Akari Malta Limited Malta Peak Bio Inc. Delaware Peak Bio Co., Ltd. Republic of Korea Ignyte |
|
| March 30, 2026 |
Exhibit 3.1 AKARI THERAPEUTICS, PLC Company No. 05252842 ARTICLES OF ASSOCIATION The Companies Act 2006 Public Company Limited by Shares (Adopted by Special Resolution of the Company passed on 15 December 2025) TABLE OF CONTENTS 1. Preliminary 1 2. Liability of members 3 3. Share capital and variation of rights 3 4. Certificates and shares 4 5. Uncertificated Shares 5 6. Calls on shares 6 7. Trans |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Therapeut |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 Akari Therapeutics, Plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-36288 98-1034922 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 17, 2026 |
Akari Therapeutics Announces ADS Ratio Change Exhibit 99.1 Akari Therapeutics Announces ADS Ratio Change TAMPA, FL and LONDON – March 17, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss |
|
| February 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| January 27, 2026 |
January 27, 2026 Abizer Gaslightwala Chief Executive Officer Akari Therapeutics, Plc 401 East Jackson St, Suite 3300 Tampa, FL 33602 Re: Akari Therapeutics, Plc Registration Statement on Form S-1 Filed January 23, 2026 File No. |
|
| January 27, 2026 |
Akari Therapeutics, Plc 401 East Jackson St, Suite 3300 Tampa, FL 33602 January 27, 2026 Akari Therapeutics, Plc 401 East Jackson St, Suite 3300 Tampa, FL 33602 January 27, 2026 VIA EDGAR U. |
|
| January 23, 2026 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) AKARI THERAPEUTICS PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Ordinary Shares, $0. |
|
| January 23, 2026 |
As filed with the Securities and Exchange Commission on January 23, 2026 As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. |
|
| January 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 17, 2025 |
Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 17, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 16, 2025, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collect |
|
| December 17, 2025 |
Exhibit 10.6 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 17, 2025 |
NOTE CANCELLATION AND EXCHANGE AGREEMENT Exhibit 10.7 NOTE CANCELLATION AND EXCHANGE AGREEMENT This NOTE CANCELLATION AND EXCHANGE AGREEMENT (this “Agreement”) is entered into as of December [●], 2025 (the “Effective Date”) by and between [●], an [individual][description of entity] (“Noteholder”) and AKARI THERAPEUTICS, PLC, a public company limited by shares incorporated in England and Wales (the “Company”). WHEREAS, in August 2025, Not |
|
| December 17, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December [], 2025, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collect |
|
| December 17, 2025 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT December 16, 2025 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), hereby agrees to sell up to an aggr |
|
| December 17, 2025 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com |
|
| December 17, 2025 |
Exhibit 99.1 Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market – New cash portion of offering includes >20% participation from Directors, Officers and Executive Management TAMPA, Fla. and LONDON – December 16, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company devel |
|
| December 17, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-289056 Prospectus Supplement (to Prospectus dated July 31, 2025) Akari Therapeutics, PLC 10,043,774 American Depositary Shares Representing 20,087,548,000 Ordinary Shares Akari Therapeutics, PLC (the “Company” or “we” or “our” or “us”) is offering (“Offering”) to certain investors (the “investors”) 10,043,774 American Depository Shares (the “AD |
|
| December 17, 2025 |
Exhibit 10.8 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com |
|
| December 8, 2025 |
Exhibit 99.1 |
|
| December 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2025 Akari Therapeutics, Plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-36288 98-1034922 (State or Other Jurisdiction of Incorporation) ( |
|
| December 5, 2025 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-291596 PROSPECTUS Akari Therapeutics, PLC 12,750,000,000 Ordinary Shares Represented by 6,375,000 American Depositary Shares This prospectus relates to the resale, from time to time, by the selling shareholders identified in this prospectus, or the selling shareholders, of up to an aggregate of 12,750,000,000 ordinary shares, par valu |
|
| December 1, 2025 |
Akari Therapeutics, Plc 401 E Jackson St, Suite 3300 Tampa, FL 33602 December 1, 2025 Akari Therapeutics, Plc 401 E Jackson St, Suite 3300 Tampa, FL 33602 December 1, 2025 VIA EDGAR U. |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2025 Akari Therapeutics, Plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-36288 98-1034922 (State or Other Jurisdiction of Incorporation) |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 17, 2025 |
As filed with the Securities and Exchange Commission on November 17, 2025 As filed with the Securities and Exchange Commission on November 17, 2025 Registration No. |
|
| November 17, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) AKARI THERAPEUTICS PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Ordinary Shares, $0. |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Akari Therapeutics, Plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-36288 98-1034922 (State or Other Jurisdiction of Incorporation) ( |
|
| October 23, 2025 |
Akari Therapeutics Consulting Agreement Exhibit 10.1 Akari Therapeutics Consulting Agreement This Consulting Agreement (this “Agreement”) is made as of October 20, 2025 (the “Effective Date”), by and between Akari Therapeutics Plc, having a place of business at 401 Jackson Street, Suite 3300, Tampa, FL 33602 (the “Company” or “Akari”), KDF Ventures LLC having a place of business at 209 S. EL Portal Street, Encinitas, CA 92024 (the “Cons |
|
| October 16, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 14, 2025, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collecti |
|
| October 16, 2025 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm |
|
| October 16, 2025 |
Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 16, 2025 |
PLACEMENT AGENCY AGREEMENT October 14, 2025 Exhibit 10.2 PLACEMENT AGENCY AGREEMENT October 14, 2025 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), hereby agrees to sell up to an aggre |
|
| October 16, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-289056 Prospectus Supplement (to Prospectus dated July 31, 2025) Akari Therapeutics, PLC 3,125,000 American Depositary Shares Representing 6,250,000,000 Ordinary Shares Akari Therapeutics, PLC (the “Company” or “we” or “our” or “us”) is offering (“Offering”) to certain investors (the “investors”) 3,125,000 American Depository Shares (the “ADSs” |
|
| October 16, 2025 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 15, 2025 |
Akari Therapeutics Announces $2.5 Million Registered Direct Offering Exhibit 10.1 Akari Therapeutics Announces $2.5 Million Registered Direct Offering BOSTON and LONDON – October 15, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000 of the Compa |
|
| October 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2025 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2025 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Co |
|
| September 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2025 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Co |
|
| September 25, 2025 |
Exhibit 10.1 AKARI THERAPEUTICS, PLC September 19, 2025 Re: Unsecured Convertible Promissory Note and Warrant Issued in April 2023 Dear [●]: Pursuant to the Unsecured Convertible Promissory Note (the “Note”) attached hereto as Exhibit A, issued by Peak Bio, Inc. (“Peak Bio”), to you (“Holder”, “you” or similar terminology), in the principal amount of $[●], which was assumed by Akari Therapeutics, |
|
| August 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) AKARI THERAPEUTICS PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (2) (3) Fee Rate Amount of Registration Fee Equity American Depositary Shares (“ADSs”), each representing 2,000 Ordinary Shares, $0. |
|
| August 29, 2025 |
ORDINARY SHARE PURCHASE AGREEMENT Exhibit 10.3 ORDINARY SHARE PURCHASE AGREEMENT This Ordinary Share Purchase Agreement (this “Agreement”) is entered into effective as August 29, 2025 (the “Execution Date”), by and between Akari Therapeutics, Plc, public limited company incorporated under the laws of England and Wales (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”). WHEREAS, the pa |
|
| August 29, 2025 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is entered into effective as August 29, 2025 (the “Execution Date”), by and between Akari Therapeutics, Plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”). RECITALS A. WHEREAS, |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi |
|
| August 29, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is entered into effective as August 29, 2025 (the “Execution Date”), by and between Akari Therapeutics, Plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”). RECITALS A. WHEREAS, |
|
| August 29, 2025 |
ORDINARY SHARE PURCHASE AGREEMENT Exhibit 10.1 ORDINARY SHARE PURCHASE AGREEMENT This Ordinary Share Purchase Agreement (this “Agreement”) is entered into effective as August 29, 2025 (the “Execution Date”), by and between Akari Therapeutics, Plc, public limited company incorporated under the laws of England and Wales (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”). WHEREAS, the pa |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi |
|
| August 21, 2025 |
LOAN CANCELLATION AND EXCHANGE AGREEMENT Exhibit 10.1 LOAN CANCELLATION AND EXCHANGE AGREEMENT This LOAN CANCELLATION AND EXCHANGE AGREEMENT (this “Agreement”) is entered into as of August 7, 2025 (the “Effective Date”) by and among DR. HOYOUNG HUH, an individual (“Dr. Huh”), AKARI THERAPEUTICS, PLC, a public company limited by shares incorporated in England and Wales (the “Company”), and PEAK BIO INC, a Delaware corporation and wholly-o |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi |
|
| August 19, 2025 |
Exhibit 99.1 |
|
| August 13, 2025 |
Form of Amendment No. 1 to Series A Warrant. Exhibit 10.4 August [●], 2025 AMENDMENT NO. 1 TO SERIES A WARRANT This Amendment No. 1 (this “Amendment”) to the Series A Warrant (as defined below), is made by and between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and (the “Holder”). WHEREAS, the Holder is the holder of outstanding Series A Warrant to purchas |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Thera |
|
| August 13, 2025 |
Form of August 2025 Note Purchase Agreement. Exhibit 10.2 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”), dated as of August [●], 2025, is entered into by and between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and the buyer set forth on the signature page(s) hereto (the “Buyer”). RECITALS On the terms and subject to the conditions |
|
| August 13, 2025 |
Form of 20% Original Issue Discount Promissory Note. Exhibit 10.3 20% ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. AKA |
|
| July 30, 2025 |
July 30, 2025 Abizer Gaslightwala President and Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed July 29, 2025 File No. |
|
| July 30, 2025 |
Akari Therapeutics, PLC 22 Boston Wharf Road Fl. 7 Boston, MA 02210 Akari Therapeutics, PLC 22 Boston Wharf Road Fl. 7 Boston, MA 02210 July 30, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Akari Therapeutics PLC Registration Statement on Form S-3 File No. 333-289056 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics PLC (the |
|
| July 29, 2025 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fees Previously Paid Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value $0. |
|
| July 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Akari Therapeutics, PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, par value $0. |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025 As filed with the Securities and Exchange Commission on July 29, 2025 Registration No. |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025. As filed with the Securities and Exchange Commission on July 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 98-1034922 (State or other jurisdiction of incorporation or organization) |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss |
|
| July 1, 2025 |
Amendment No. 2 to the Akari Therapeutics, PLC 2023 Equity Incentive Plan Exhibit 10.1 AMENDMENT NO. 2 TO THE AKARI THERAPEUTICS, PLC 2023 EQUITY INCENTIVE PLAN WHEREAS, Akari Therapeutics, plc (the “Company”) maintains the Akari Therapeutics, plc 2023 Equity Incentive Plan (the “Plan”) which was previously adopted by the Board of Directors of the Company (the “Board”) and approved by the Company’s shareholders; WHEREAS, the Board believes that the number of shares of C |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Thera |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 15, 2025 |
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing new Head of Business Development - Oncology BOSTON and LONDON – May 15, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi |
|
| May 14, 2025 |
March 13, 2025 Abizer Gaslightwala Re: Offer of Employment by Akari Therapeutics, Plc Dear Abizer: On behalf of Akari Therapeutics, Plc (the “Company”), I am pleased to confirm our offer to employ you as Chief Executive Officer. |
|
| May 14, 2025 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-287012 PROSPECTUS AKARI THERAPEUTICS, PLC 51,770,782,000 Ordinary Shares Represented by 25,885,391 American Depositary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 25,885,391 American Depositary Shares, or ADSs, representing up to an aggregate of 51,7 |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Ther |
|
| May 12, 2025 |
Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 May 12, 2025 Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 May 12, 2025 VIA EDGAR U. |
|
| May 9, 2025 |
May 9, 2025 Abizer Gaslightwala President and Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed May 6, 2025 File No. |
|
| May 6, 2025 |
As filed with the Securities and Exchange Commission on May 6, 2025 Registration No. |
|
| May 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2)(3) Equity Ordinary Shares, $0. |
|
| April 16, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commis |
|
| April 16, 2025 |
Exhibit 99.1 Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC |
|
| April 15, 2025 |
Exhibit 10.40 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. August 18, 2024 PERSONAL AND CONFIDENTIAL Rachelle Jacques [***] Re: Separation Agreement Dear Rachelle, |
|
| April 15, 2025 |
Consulting Agreement between the Company and Wendy DiCicco dated July 17, 2023. Exhibit 10.26 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement ("Agreement") isentered into as of July 17, 2023 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 1460 Broadway, New York, NY 10036 ("Akari"). Consultant and Akari are each referredto individually |
|
| April 15, 2025 |
Exhibit 4.7 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description is a summary of the material terms of Akari Therapeutics, Plc’s (the “Company”) ordinary shares with a par value $0.0001 per share and American Depositary Shares (the “ADSs”), each representing 2,000 ordinary shares. This description also summarizes r |
|
| April 15, 2025 |
Restricted Stock Unit Agreement between the Company and Rachelle Jacques dated June 1, 2023. Exhibit 10.25 AKARI THERAPEUTICS, PLC 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT PARTICIPANT: Rachelle Jacques NUMBER OF RSUs: 218,055,800 DATE OF GRANT: June 30, 2023 Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), is pleased to confirm that the Participant has been granted a Restricted Stock Unit Award (this “Award”), |
|
| April 15, 2025 |
Exhibit 10.27 AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT This Amendment No. 1 (“Amendment”) is entered into as of September 1, 2023 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 ("Akari"), and amends the Consulting Agreem |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Therapeut |
|
| April 15, 2025 |
Stock Option Agreement between the Company and Wendy F. DiCicco dated July 17, 2023. Exhibit 10.29 STOCK OPTION AGREEMENT United States Participants (NSO) AGREEMENT made as of the date of the grant set forth in Exhibit A (the “Effective Date”) by and between Akari Therapeutics, Plc, a company formed under the laws of England and Wales, and having a place of business at 22 Boston Wharf Road, Floor 7, Boston, MA 02210, USA (the “Company”) and the individual whose name and address ap |
|
| April 15, 2025 |
AKARI THERAPEUTICS PLC INSIDER TRADING POLICY Akari Therapeutics, Plc (the “Company”) has adopted the following policy regarding trading by Company personnel in the Company’s securities (the “Insider Trading Policy,” or this “Policy”). |
|
| April 15, 2025 |
Exhibit 97 Akari Therapeutics, Plc Executive Officer Clawback Policy Approved by the Board of Directors on November 27, 2023 (the “Adoption Date”) I. |
|
| April 15, 2025 |
Exhibit 21.1 Subsidiaries of Akari Therapeutics, Plc The following table sets forth the name and jurisdiction of incorporation of our subsidiaries: Name of Subsidiary Jurisdiction of Incorporation Celsus Therapeutics Inc. Delaware Morria Biopharma Ltd. Israel Volution Immuno Pharmaceuticals SA Switzerland Akari Malta Limited Malta Peak Bio Inc. Delaware Peak Bio Co., Ltd. Republic of Korea Ignyte |
|
| April 15, 2025 |
Consulting Agreement between the Company and Wendy F. DiCicco dated January 15, 2024. Exhibit 10.28 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement ("Agreement") is entered into as of January 15, 2024 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road FL 7, Boston, MA 02210 ("Akari"). Consultant and Akari are each referred |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-36288 CUSIP NUMBER 00972G207 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra |
|
| March 20, 2025 |
March 18, 2025 Abizer Gaslightwala Re: Clarifications for the Offer of Employment by Akari Therapeutics, Plc Dear Abizer: Please accept this letter of clarification to your Offer of Employment by Akari Therapeutics, Plc dated March 13, 2025, and fully executed as of March 17, 2025 (the “Agreement”). |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commis |
|
| March 20, 2025 |
March 13, 2025 Abizer Gaslightwala Re: Offer of Employment by Akari Therapeutics, Plc Dear Abizer: On behalf of Akari Therapeutics, Plc (the “Company”), I am pleased to confirm our offer to employ you as Chief Executive Officer. |
|
| March 3, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 3, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 2, 2025 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively |
|
| March 3, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 3, 2025 |
Exhibit 4.3 Series B Warrant NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN |
|
| March 3, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm |
|
| January 13, 2025 |
Corporate Presentation January 2025 NASDAQ: AKTX akaritx.com Next-Generation Precision Bi-Functional Antibody Drug Conjugates Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about th |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm |
|
| December 6, 2024 |
SC 13D/A 1 ea0223686-13da1patelakari.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 Akari Therapeutics, PLC (Name of Issuer) Ordinary Shares, par value $0.0001 per share (represented by American Depositary Shares) (Title of Class of Securities) 00972G207 (CUSIP Num |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39290 CUSIP NUMBER 97382D 501 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T |
|
| November 14, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Merger with Peak Bio On March 4, 2024, Akari Therapeutics, Plc (“Akari”) entered into an Agreement and Plan of Merger with Peak Bio and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Pegasus Merger Sub”), as amended by that certain side letter dated August 15, 2024 (the “Merger Agree |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com |
|
| November 14, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 14, 2024 |
Exhibit 99.1 Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and LONDON, November 14, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX) announces the completion of the merger (the Merger) of Akari Therapeutics, Plc |
|
| November 14, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 13, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collecti |
|
| November 8, 2024 |
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger Exhibit 99.1 Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger BOSTON and LONDON, November 8, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the C |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm |
|
| October 15, 2024 |
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger BOSTON and LONDON, October 14, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. |
|
| October 11, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-282127 MERGER PROPOSED - YOUR VOTE IS VERY IMPORTANT Akari Therapeutics, Plc Registered office: Highdown House Yeoman Way, Worthing, West Sussex, BN99 3HH, United Kingdom Incorporated in England & Wales with registered no. 05252842 October 11, 2024 Dear Akari Therapeutics, Plc Shareholder: This letter, the notice of the genera |
|
| October 9, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on October 9, 2024 Registration No. |
|
| October 9, 2024 |
Exhibit 10.27 AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT This Amendment No. 1 (“Amendment”) is entered into as of April 26, 2024 (“Effective Date”) by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 (“Consultant”), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 (“Akari”), and amends the Consulting Services |
|
| October 9, 2024 |
CORRESP October 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Akari Therapeutics, Plc Registration Statement on Form S-4 File No. 333-282127 Dear Mr. Gorsky: In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, |
|
| October 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, $0. |
|
| October 4, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi |
|
| September 30, 2024 |
CORRESP Goodwin Procter LLP One Commerce Square 2005 Market Street, 32nd Floor Philadelphia, PA 19103 goodwinlaw. |
|
| September 30, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on September 27, 2024 Registration No. |
|
| September 26, 2024 |
September 26, 2024 Samir R. Patel, M.D. Interim President and Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road, FL7 Boston, MA 02210 Re: Akari Therapeutics, Plc Registration Statement on Form S-4 Filed September 13, 2024 File No. 333-282127 Dear Samir R. Patel M.D.: We have conducted a limited review of your registration statement and have the following comments. Please respond |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Co |
|
| September 18, 2024 |
Exhibit 99.1 BUSINESS OF AKARI Overview Akari is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (“C5”) and leukotriene B4 (“LTB4”) pathways. Each of these pathways has scientifically well-supported causative roles in the diseases we are targeting. Akari believes that blocking these two early mediators o |
|
| September 18, 2024 |
Exhibit 10.1 AMENDMENT TO INTERIM CHIEF EXECUTIVE OFFICER AGREEMENT This Amendment (this “Amendment”) to the Interim Chief Executive Officer Agreement (the “Interim CEO Agreement”), effective May 1, 2024, between Samir R. Patel, M.D. (“Interim CEO”) and Akari Therapeutics, Plc (the “Company”) is effective as of July 1, 2024. All capitalized terms used herein but not otherwise defined shall have th |
|
| September 16, 2024 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| September 13, 2024 |
Exhibit 99.3 Consent of Person Named as About to Become Director September 13, 2024 Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Akari Therapeutics, Plc, and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under t |
|
| September 13, 2024 |
As filed with the Securities and Exchange Commission on September 13, 2024 Registration No. |
|
| September 13, 2024 |
Exhibit 10.35 AMENDMENT TO INTERIM CHIEF EXECUTIVE OFFICER AGREEMENT This Amendment (this “Amendment”) to the Interim Chief Executive Officer Agreement (the “Interim CEO Agreement”), effective May 1, 2024, between Samir R. Patel, M.D. (“Interim CEO”) and Akari Therapeutics, Plc (the “Company”) is effective as of July 1, 2024. All capitalized terms used herein but not otherwise defined shall have t |
|
| September 13, 2024 |
Exhibit 99.4 Consent of Person Named as About to Become Director September 13, 2024 Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Akari Therapeutics, Plc, and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under t |
|
| September 13, 2024 |
Consent of Hoyoung Huh, MD, PhD Exhibit 99.1 Consent of Person Named as About to Become Director September 13, 2024 Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Akari Therapeutics, Plc, and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under t |
|
| September 13, 2024 |
Consent of James Neal, MS, MBA Exhibit 99.2 Consent of Person Named as About to Become Director September 13, 2024 Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Akari Therapeutics, Plc, and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under t |
|
| September 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee (4) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, $0. |
|
| September 11, 2024 |
September 11, 2024 Samir R. Patel Chief Executive Officer Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed September 6, 2024 File No. 333-281995 Dear Samir R. Patel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding reques |
|
| September 11, 2024 |
Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 September 11, 2024 Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 September 11, 2024 VIA EDGAR U. |
|
| September 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2) (3) Equity Ordinary Shares, $0. |
|
| September 6, 2024 |
AKARI THERAPEUTICS, PLC UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.3 AKARI THERAPEUTICS, PLC UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On March 4, 2024, Akari Therapeutics, Plc, a public company limited, with shares incorporated in England and Wales (“Akari”), and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Merger Sub”), entered into a definitive agreement to acquire Peak Bio Inc., a Delaw |
|
| September 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com |
|
| September 6, 2024 |
PEAK BIO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS Exhibit 99.2 PEAK BIO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30 December 31 2024 2023 (Unaudited) Assets Current assets Cash $ 235,774 $ 381,649 Prepaid expenses and other current assets 1,095,939 1,992,458 Total current assets 1,331,713 2,374,107 Property and equipment, net 31,807 153,108 Restricted cash 60,000 60,000 Other noncurrent assets 11,136 9,200 Total assets $ 1,434,656 $ 2,596 |
|
| September 6, 2024 |
PEAK BIO Consolidated Financial Statements As of and for the Years Ended December 31, 2023 and 2022 Exhibit 99.1 PEAK BIO Consolidated Financial Statements As of and for the Years Ended December 31, 2023 and 2022 Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 688) F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations and Comprehensive Loss F-4 Consolidated Statements of Equity (Deficit) F-5 Consolidated Statements of Cash Flows F-6 Notes to Consolidat |
|
| September 6, 2024 |
As filed with the Securities and Exchange Commission on September 6, 2024 Table of Contents As filed with the Securities and Exchange Commission on September 6, 2024 Registration No. |
|
| September 6, 2024 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 27, 2023, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collect |
|
| September 6, 2024 |
Exhibit 4.9 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND ARE “RESTRICTED SECURITIES” AS DEFINED IN RULE 144 PROMULGATED UNDER THE ACT. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE DISTRIBUTED OR TRANSFERRED EXCEPT (i) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR (ii) PURSUANT TO AN |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm |
|
| August 19, 2024 |
Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance |
|
| August 19, 2024 |
Exhibit 10.5 August 15, 2024 Side Letter Agreement Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Attention: Samir R. Patel, M.D. Pegasus Merger Sub, Inc. 22 Boston Wharf Road FL 7 Boston, MA 02210 Attention: Samir R. Patel, M.D. Peak Bio, Inc. 4900 Hopyard Road, Suite100 Pleasanton, CA 94588 Attention: Hoyoung Huh Re : Extension of Merger Agreement Termination Date Ladies and |
|
| August 19, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Thera |
|
| August 19, 2024 |
Exhibit 10.3 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO MAKER THAT REGISTRATI |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39290 CUSIP NUMBER 97382D 501 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| July 1, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Akari Therapeutics, Plc (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 00972G207 (CUSIP Number) Jennifer L. Porter, Esquire Justin S. Platt, Esquire Goodwin Procter LLP 620 8th Ave New York, NY 10018 +1 212 813 8800 |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Akari Therapeutics Plc (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 00972G207 (CUSIP Number) Jay H. Knight Barnes & Thornburg LLP 1600 West End Avenue, Suite 800 Nashville, Tennessee 37203-3494 (615) 621-610 |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Akari Therapeutics, PLC (Name of Issuer) Ordinary Shares, par value $0.0001 per share (represented by American Depositary Shares) (Title of Class of Securities) 00972G207 (CUSIP Number) Rob Condon Dentons US LLP 1221 Avenue of the Americas New York, NY 10020 (212) 768-670 |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi |
|
| June 5, 2024 |
Exhibit 10.1 INTERIM CHIEF EXECUTIVE OFFICER AGREEMENT Effective May 1, 2024, (the “Start Date”), Samir R. Patel, M.D. (“Interim CEO”) and Akari Therapeutics, Plc (the “Company”) agree as follows:a 1. Services; Payment; No Violation of Rights or Obligations. Interim CEO agrees to undertake and complete the Services (as defined in Exhibit A) in accordance with and on the schedule specified in Exhib |
|
| June 4, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi |
|
| June 4, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ցց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR տտ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Therape |
|
| June 4, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 29, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively |
|
| June 4, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 4, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 4, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 29, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 16, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi |
|
| May 16, 2024 |
Exhibit 99.1 Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Implementation of Restr |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Ther |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissio |
|
| May 1, 2024 |
Exhibit 10.1 AMENDMENT NO. 2 TO CONSULTING SERVICES AGREEMENT This Amendment No. 2 (“Amendment”) is entered into as of April 26, 2024 (“Effective Date”) by and between Board Advantage LLC, with an address of (“Consultant”), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 (“Akari”), and amends the Consulting Agreement dated July 17, 2023 and Amendment #1 dated S |
|
| May 1, 2024 |
Exhibit 99.1 Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity • Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease • Akari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, May 1, 2024 (GLOBE NEW |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commis |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commis |
|
| May 1, 2024 |
Exhibit 99.1 Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity • Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease • Akari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, May 1, 2024 (GLOBE NEW |
|
| May 1, 2024 |
AMENDMENT NO. 2 TO CONSULTING SERVICES AGREEMENT Exhibit 10.1 AMENDMENT NO. 2 TO CONSULTING SERVICES AGREEMENT This Amendment No. 2 (“Amendment”) is entered into as of April 26, 2024 (“Effective Date”) by and between Board Advantage LLC, with an address of (“Consultant”), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 (“Akari”), and amends the Consulting Agreement dated July 17, 2023 and Amendment #1 dated S |
|
| April 11, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss |
|
| April 1, 2024 |
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights Exhibit 99.1 Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights BOSTON and LONDON, April 1, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. “Amidst challe |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss |
|
| March 29, 2024 |
Stock Option Agreement between the Company and Rachelle Jacques dated March 28, 2023. Exhibit 10.24 AKARI THERAPEUTICS, PLC 2014 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT PARTICIPANT: Rachelle Jacques NUMBER OF RSUs: 189,787,200 DATE OF GRANT: March 28, 2023 Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), is pleased to confirm that the Participant has been granted a Restricted Stock Unit Award (this “Award”), |
|
| March 29, 2024 |
Exhibit 10.27 AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT This Amendment No. 1 (“Amendment”) is entered into as of September 1, 2023 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 ("Akari"), and amends the Consulting Agreem |
|
| March 29, 2024 |
Consulting Agreement between the Company and Wendy F. DiCicco dated January 15, 2024. Exhibit 10.28 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement ("Agreement") is entered into as of January 15, 2024 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road FL 7, Boston, MA 02210 ("Akari"). Consultant and Akari are each referred |
|
| March 29, 2024 |
Exhibit 10.29 STOCK OPTION AGREEMENT United States Participants (NSO) AGREEMENT made as of the date of the grant set forth in Exhibit A (the “Effective Date”) by and between Akari Therapeutics, Plc, a company formed under the laws of England and Wales, and having a place of business at 22 Boston Wharf Road, Floor 7, Boston, MA 02210, USA (the “Company”) and the individual whose name and address ap |
|
| March 29, 2024 |
Exhibit 4.7 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description is a summary of the material terms of Akari Therapeutics, Plc (the “Company”) ordinary shares with a par value $0.0001 per share and American Depositary Shares (the “ADSs”), each representing 2,000 ordinary shares. This description also summarizes rel |
|
| March 29, 2024 |
Consulting Agreement between the Company and Wendy DiCicco dated July 17, 2023. Exhibit 10.26 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement ("Agreement") isentered into as of July 17, 2023 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 1460 Broadway, New York, NY 10036 ("Akari"). Consultant and Akari are each referredto individually |
|
| March 29, 2024 |
Exhibit 97 Akari Therapeutics, Plc Executive Officer Clawback Policy Approved by the Board of Directors on November 27, 2023 (the “Adoption Date”) I. |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Therapeut |
|
| March 29, 2024 |
Exhibit 10.7 AKARI THERAPEUTICS, PLC 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT PARTICIPANT: NUMBER OF RSUs: DATE OF GRANT: Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), is pleased to confirm that the Participant has been granted a Restricted Stock Unit Award (this “Award”), effective as of the Date of Grant set forth |
|
| March 29, 2024 |
Exhibit 10.6 STOCK OPTION AGREEMENT United States Participants (ISO/NSO) AGREEMENT made as of the date of the grant set forth in Exhibit A (the “Effective Date”) by and between Akari Therapeutics, Plc, a company formed under the laws of England and Wales, and having a place of business at 22 Boston Wharf Road, Floor 7, Boston, MA 02210, USA (the “Company”) and the individual whose name and address |
|
| March 29, 2024 |
Restricted Stock Unit Agreement between the Company and Rachelle Jacques dated June 1, 2023. Exhibit 10.25 AKARI THERAPEUTICS, PLC 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT PARTICIPANT: Rachelle Jacques NUMBER OF RSUs: 218,055,800 DATE OF GRANT: June 30, 2023 Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), is pleased to confirm that the Participant has been granted a Restricted Stock Unit Award (this “Award”), |
|
| March 29, 2024 |
Exhibit 21.1 Subsidiaries of Akari Therapeutics, Plc The following table sets forth the name and jurisdiction of incorporation of our subsidiaries: Name of Subsidiary Jurisdiction of Incorporation Celsus Therapeutics Inc. Delaware Morria Biopharma Ltd. Israel Volution Immuno Pharmaceuticals SA Switzerland Akari Malta Limited Malta |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2024 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 NA (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 11, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 11, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectivel |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2024 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 NA (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 11, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 11, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectivel |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-36288 98-1034922 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 5, 2024 |
Exhibit 99.1 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit BOSTON, MA and PLEASANTON, CA – March 5, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and |
|
| March 5, 2024 |
Filed by Akari Therapeutics, Plc Filed by Akari Therapeutics, Plc pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Peak Bio, Inc. |
|
| March 5, 2024 |
Akari Therapeutics Company Presentation March 2024 Exhibit 99.4 Akari Therapeutics Company Presentation March 2024 2 This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger (the “Merger Ag reement”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“ Akari ”),, Pegasus Merger Sub, Inc., a Delaware corporation and a wholly - owned sub |
|
| March 5, 2024 |
Akari employee communication from Rachelle Jacques: Exhibit 99.2 Akari employee communication from Rachelle Jacques: Team, Today we issued a press release announcing that Akari and Peak Bio have reached a definitive agreement for a merger of equals in an all-stock transaction. Please see the press release here. This merger is an important step forward for our company. I’d like to discuss this with you and answer your questions personally, so we’ll |
|
| March 5, 2024 |
Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of [●], 2024 (the “Agreement Date”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“Parent”), and [Stockholder] (the “Stockholder”). Each of Parent and the Stockholder are sometimes referred to as a “Party” and coll |
|
| March 5, 2024 |
Akari investor email (those who have inquired in the past) from Rachelle Jacques: Exhibit 99.3 Akari investor email (those who have inquired in the past) from Rachelle Jacques: [Name], I wanted to reach out personally and share the news we issued this morning. Akari and Peak Bio have reached a definitive agreement for a merger of equals in an all-stock transaction. Please see the press release here. What is most exciting about this merged company, which will operate as Akari an |
|
| March 5, 2024 |
Exhibit 10.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of [●], 2024 (the “Agreement Date”), by and among Peak Bio, Inc. (the “Company”), a Delaware corporation and [SHAREHOLDER] (the “Shareholder”). Each of the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms u |
|
| March 5, 2024 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AmONG AKARI THERAPEUTICS, PLC, PEGASUS MERGER SUB, INC. AND PEAK BIO, INC. Dated as of March 4, 2024 Table of Contents Section 1 THE MERGER 2 1.1 The Merger 2 1.2 Effective Time 2 1.3 Closing 2 1.4 Directors and Officers of the Surviving Corporation 3 1.5 Subsequent Actions 3 1.6 Post-Merger Operations 3 Section 2 CONVERSION OF SECU |
|
| March 5, 2024 |
Exhibit 10.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of [●], 2024 (the “Agreement Date”), by and among Peak Bio, Inc. (the “Company”), a Delaware corporation and [SHAREHOLDER] (the “Shareholder”). Each of the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms u |
|
| March 5, 2024 |
Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of [●], 2024 (the “Agreement Date”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“Parent”), and [Stockholder] (the “Stockholder”). Each of Parent and the Stockholder are sometimes referred to as a “Party” and coll |
|
| March 5, 2024 |
Akari employee communication from Rachelle Jacques: Exhibit 99.2 Akari employee communication from Rachelle Jacques: Team, Today we issued a press release announcing that Akari and Peak Bio have reached a definitive agreement for a merger of equals in an all-stock transaction. Please see the press release here. This merger is an important step forward for our company. I’d like to discuss this with you and answer your questions personally, so we’ll |
|
| March 5, 2024 |
Akari Therapeutics Company Presentation March 2024 Exhibit 99.4 Akari Therapeutics Company Presentation March 2024 2 This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger (the “Merger Ag reement”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“ Akari ”),, Pegasus Merger Sub, Inc., a Delaware corporation and a wholly - owned sub |
|
| March 5, 2024 |
Akari investor email (those who have inquired in the past) from Rachelle Jacques: Exhibit 99.3 Akari investor email (those who have inquired in the past) from Rachelle Jacques: [Name], I wanted to reach out personally and share the news we issued this morning. Akari and Peak Bio have reached a definitive agreement for a merger of equals in an all-stock transaction. Please see the press release here. What is most exciting about this merged company, which will operate as Akari an |
|
| March 5, 2024 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AmONG AKARI THERAPEUTICS, PLC, PEGASUS MERGER SUB, INC. AND PEAK BIO, INC. Dated as of March 4, 2024 Table of Contents Section 1 THE MERGER 2 1.1 The Merger 2 1.2 Effective Time 2 1.3 Closing 2 1.4 Directors and Officers of the Surviving Corporation 3 1.5 Subsequent Actions 3 1.6 Post-Merger Operations 3 Section 2 CONVERSION OF SECU |
|
| March 5, 2024 |
Exhibit 99.1 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit BOSTON, MA and PLEASANTON, CA – March 5, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-36288 98-1034922 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 4, 2024 |
US00972G2075 / AKARI THERAPEUTICS PLC SPON ADR / RPC Pharma Ltd - SC 13D/A Activist Investment SC 13D/A 1 tm241868d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Akari Therapeutics, Plc (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 00972G207 (CUSIP Number) Gary Emmanuel, Esquire Win Rutherfurd, Esquire Greenberg Traurig, LLP One Vande |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com |
|
| January 2, 2024 |
Exhibit 99.1 Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing BOSTON and LONDON, January 2, 2024 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with exi |
|
| December 1, 2023 |
Exhibit 99.1 Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors NEW YORK and BOSTON, December 1, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 22 Boston Wharf Road FL 7 Boston, MA 02210 (Address of principal executi |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal |
